NORWAY - NeoMed-backed Clavis Pharma appoints new chairman

'We are delighted that Sven Arild Andersen has accepted his new post. With his broad international industrial experience, not the least from the pharmaceutical sector, he brings highly valuable competence and insight,' Pike, who is also partner at NeoMed, comments.

Sven Arild Andersen stepped down from his position as president and CEO of the Oslo Stock Exchange in December 2005. Prior to this assignment, Sven Arild Andersen held several managerial positions within Norsk Hydro. For a number of years he was in charge of the biomedical research of Norsk Hydro, including the technology that later was to become the scientific foundation of Clavis Pharma.

Clavis Pharma was established in 2001. It develops pharmaceuticals using its proprietary lipid vector technology.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Industrials